pharma · Metastatic Prostate Cancer · Prostate Cancer · TLX
Telix Innovations
Telix Innovations is a pharma organization headquartered in Herstal, BE. It trades on NYSE under ticker TLX. Primary therapeutic focus areas include Metastatic Prostate Cancer, Prostate Cancer, Clear Cell Renal Cell Carc
Rue de Hermée 255, Herstal, Région wallonne 4040, BE HQ
2015 Founded
14 Employees
Public company Type
TLX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Rue de Hermée 255, Herstal, Région wallonne 4040, BE
- Founded
- 2015
- Employees
- 14
- Programs
- 27
- Drugs
- 11
- Patents
- 3
89Zr-Girentuximab
Phase 3 · small molecule · Clear Cell Renal Cell Carcinoma
89Zr-Girentuximab for Clear Cell Renal Cell Carcinoma is a Phase 3 program (small_molecule) at Telix Innovations with 2 ClinicalTrials.gov record(s).
Internal code TLX250CDx-CP-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Telix Innovations
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Clear Cell Renal Cell Carcinoma
- Status
- completed
- Trials
- 2